We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLB:NYSESLB Limited Analysis

Data as of 2026-09-07 - not real-time

$57.51

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

At $57.51, SLB N.V. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. Over a rolling month the price has gained 9.7%. With RSI at 62.2 the momentum picture is approaching overbought, alongside a bullish MACD signal. Watch $50.67 as support and $60.46 as the nearer resistance level.
Valuation screens as overvalued: a P/E of 28.1 sits above the sector average of 17.8. Sell-side targets cluster 7.9% above the current quote. Revenue is growing at 5.0% on a 8.5% profit margin. The 2.05% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 37.9%, a beta of 0.73 and a maximum drawdown of 22.3%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
This one splits by horizon — buy in the near term, hold further out, at 2/10 long-term conviction.

Top Market Events

Oilfield services provider SLB NYSE:SLB reported Q2 CY2026 results , but sales fell by 4.SLB Ltd SLB reports robust digital revenue growth and strategic positioning despite geopolitical headwinds in the...SLB NYSE: SLB today announced results for the second-quarter 2026.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 49.06
  • MACD momentum is positive

Medium Term

1–3 years
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 28.1 versus sector average of 17.8
  • Trading above the 200-day average of 49.06

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 28.1 versus sector average of 17.8
  • Analyst targets imply +7.9% versus the current price
  • Dividend yield of 2.05%

Key Metrics & Analysis

Financial Health

Revenue Growth5.00%
Profit Margin8.53%
P/E Ratio28.1
ROE12.91%
ROA6.17%
Debt/Equity47.00
P/B Ratio3.3
Op. Cash Flow$6.5B
Free Cash Flow$3.0B
Industry P/E17.8

Technical Analysis

TrendBullish
RSI62.2
Support$50.67
Resistance$60.46
MA 20$54.84
MA 50$50.79
MA 200$49.06
MACDBullish
VolumeIncreasing
Fear & Greed Index94.11

Valuation

Fair Value$25.36
Target Price$62.03
Upside/Downside7.87%
GradeOvervalued
TypeBlend
Dividend Yield2.05%

Risk Assessment

Beta0.73
Volatility37.92%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.